SK25196A3 - Quinoxaline application with the combination of proteases as drugs for aids and/or hiv-infections - Google Patents

Quinoxaline application with the combination of proteases as drugs for aids and/or hiv-infections Download PDF

Info

Publication number
SK25196A3
SK25196A3 SK251-96A SK25196A SK25196A3 SK 25196 A3 SK25196 A3 SK 25196A3 SK 25196 A SK25196 A SK 25196A SK 25196 A3 SK25196 A3 SK 25196A3
Authority
SK
Slovakia
Prior art keywords
carbon atoms
alkyl
hydroxy
alkoxy
chlorine
Prior art date
Application number
SK251-96A
Other languages
English (en)
Slovak (sk)
Inventor
Arnold Paessens
Martin Blunck
Guenter Riess
Joerg-Peter Kleim
Manfred Roesner
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SK25196A3 publication Critical patent/SK25196A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK251-96A 1995-02-27 1996-02-26 Quinoxaline application with the combination of proteases as drugs for aids and/or hiv-infections SK25196A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19506742A DE19506742A1 (de) 1995-02-27 1995-02-27 Verwendung von Chinoxalinen in Kombination mit Protease-Inhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen

Publications (1)

Publication Number Publication Date
SK25196A3 true SK25196A3 (en) 1997-05-07

Family

ID=7755115

Family Applications (1)

Application Number Title Priority Date Filing Date
SK251-96A SK25196A3 (en) 1995-02-27 1996-02-26 Quinoxaline application with the combination of proteases as drugs for aids and/or hiv-infections

Country Status (19)

Country Link
EP (1) EP0728481A3 (hu)
JP (1) JPH08245392A (hu)
KR (1) KR960030951A (hu)
CN (1) CN1141196A (hu)
AR (1) AR003923A1 (hu)
AU (1) AU710158B2 (hu)
BR (1) BR9600809A (hu)
CA (1) CA2170222A1 (hu)
CZ (1) CZ57896A3 (hu)
DE (1) DE19506742A1 (hu)
FI (1) FI960850A (hu)
HR (1) HRP960070A2 (hu)
HU (1) HUP9600455A3 (hu)
IL (1) IL117247A (hu)
NO (1) NO960775L (hu)
NZ (1) NZ286058A (hu)
PL (1) PL312908A1 (hu)
SK (1) SK25196A3 (hu)
ZA (1) ZA961516B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2270546A1 (en) * 1996-11-08 1998-05-22 Japan Energy Corporation Aids remedy
DE19703131A1 (de) * 1997-01-29 1998-07-30 Bayer Ag Verwendung von Chinoxalin in Dreier-Kombination mit Protease-Inhibitoren und Reverse Transkriptaseinhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen
US6635626B1 (en) 1997-08-25 2003-10-21 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US6235740B1 (en) 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
WO1999045009A1 (en) * 1998-03-04 1999-09-10 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
AU6329599A (en) * 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
GB9911887D0 (en) * 1999-05-21 1999-07-21 Glaxo Group Ltd Methods and medicaments for post exposure prophylaxis of an hiv infection
DE10013318A1 (de) * 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
AU2003295605A1 (en) 2002-11-19 2004-06-15 Achillion Pharmaceuticals, Inc. Substituted aryl thioureas and releated compounds; inhibitors of viral replication
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
US7351709B2 (en) 2004-06-09 2008-04-01 Wyeth Estrogen receptor ligands
US20160193206A1 (en) * 2012-12-20 2016-07-07 Bayer Pharma Aktiengesellschaft Bet-protein-inhibiting dihydropyridopyrazinones
DE102017005089A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
DE102017005091A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE205837T1 (de) * 1991-04-15 2001-10-15 Aventis Pharma Gmbh Chinoxaline, verfahren zu ihrer herstellung und ihre verwendung

Also Published As

Publication number Publication date
NZ286058A (en) 1998-09-24
KR960030951A (ko) 1996-09-17
EP0728481A2 (de) 1996-08-28
NO960775D0 (no) 1996-02-26
PL312908A1 (en) 1996-09-02
AU4561596A (en) 1996-09-05
FI960850A (fi) 1996-08-28
DE19506742A1 (de) 1996-08-29
NO960775L (no) 1996-08-28
ZA961516B (en) 1996-09-03
IL117247A (en) 2000-10-31
AR003923A1 (es) 1998-09-30
CN1141196A (zh) 1997-01-29
JPH08245392A (ja) 1996-09-24
HU9600455D0 (en) 1996-04-29
HUP9600455A3 (en) 1998-04-28
AU710158B2 (en) 1999-09-16
EP0728481A3 (de) 1998-07-08
HUP9600455A2 (en) 1996-12-30
BR9600809A (pt) 1997-12-23
CZ57896A3 (en) 1996-09-11
CA2170222A1 (en) 1996-08-28
IL117247A0 (en) 1996-06-18
HRP960070A2 (en) 1997-10-31
FI960850A0 (fi) 1996-02-23

Similar Documents

Publication Publication Date Title
SK25196A3 (en) Quinoxaline application with the combination of proteases as drugs for aids and/or hiv-infections
CA3183081A1 (en) Combination therapy for treatment of cancer
SK99899A3 (en) Quinoxaline in triple combination with protease inhibitors and reverse transcriptase inhibitors as medicines for treating aids
AU737038B2 (en) Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof
HUP0203870A2 (hu) Adenozinreceptor agonistát vagy antagonistát tartalmazó gyógyászati készítmény
RU2004138819A (ru) Ингибиторы протеинкиназ jak и cdk2
AU4182200A (en) Thiadiazolyl urea or thiourea derivatives for antiviral treatment
WO2013173283A1 (en) Dosage regimen for a pi-3 kinase inhibitor
US8008288B2 (en) Anti-inflammatory A-aminocyclolactam compounds
JP2015506904A (ja) キナゾリノン類似体及び特定のウイルス感染症の治療又は予防へのキナゾリノン類似体の使用
JP2002502826A (ja) Ｈｉｖ感染の治療用組成物および方法
Cheng To market, to market-1995
JP2023550641A (ja) ウイルス感染症の治療に使用するためのｖｓｐ３４阻害剤としてのモルホリノ誘導体
JP2023550638A (ja) ウイルス感染症の処置に使用するための、ｖｓｐ３４阻害剤としてのモルホリノ誘導体
CZ269699A3 (cs) Chinoxaliny v trojité kombinaci s inhibitory proteas a inhibitory reversní transkriptasy jako léčiva pro ošetření AIDS
EP0830862A1 (en) Anti-hiv drugs
EP0774969B1 (en) Hiv protease inhibitor combination
EP1257261B1 (en) Antiviral pharmaceutical compositions containing iron chelators
MXPA99007077A (en) Quinoxaline in triple combination with protease inhibitors and reverse transcriptase inhibitors as medicines for treating aids
JPH07508997A (ja) 抗ウイルス剤の組み合わせ
EP0971715A1 (en) Mixtures of at least two reverse transcriptase inhibitors and hydroxycarbamide, in particular for inhibiting retroviral spread
HUT72493A (en) Combinations of retroviral inhibitors
US20140301979A1 (en) Anti-arenaviral compounds
WO2001030388A1 (fr) Agents permettant de soulager la tension d'un muscle ciliaire
JP2001509786A (ja) Ｈｉｖの治療に使用するためのｖｘ４７８、ジドブジン、および／または１５９２ｕ８９を含んでなる組合わせ